Water Research Laboratory

What is this project about?

Current research points towards the likely existence of water structures which, although being largely unexplored, in principle have the necessary characteristics to explain the mechanism of action of homeopathic medicines.

The Water Research Laboratory aims to investigate these new water structures using a multidisciplinary approach involving theoretical physics, mathematical modelling and experimental exploration.

In the field of the physics of high dilutions, which has immediate relevance to homeopathy, many research groups have reported interesting findings. In particular, Prof Luc Montagnier (who won the Nobel Prize for discovering the HIV/AIDS virus), has shown homeopathic dilutions to have electromagnetic properties which differ from those of normal water1,2.

Benveniste was a eminent French immunologist, adviser to the French government on scientific issue, he was the director of INSERM unit 200, directed at immunology, allergy and inflammation.

In a seminal paper published in the prestigious journal Nature in 1988, Dr Benveniste’s team of  reported their results investigating the effects of high-dilutions on human basophils (a type of white blood cell). They diluted a solution of human anti-IgE antibodies in water to such a degree that there was virtually no possibility that a single molecule of the antibody remained in the water solution. They reported, human basophils responded to the solutions just as though they had encountered the original antibody (part of the allergic reaction). The effect was reported only when the solution was shaken violently during dilution.

This publication led to a large controversy around ‘the memory of water‘. Since then 28 scientific papers have been published in this area, 23 of which reported positive results. Of the 11 publications judged to be of high quality, 8 (72%) reported positive results.4

The initial efforts of the HRI/WRL collaboration are centered around repeating the famous basophil degranulation experiments of the late Dr Jacques Benveniste (1935-2004)3, with the aim of making the experiment more easily reproducible in standard laboratory setting and of studying important physical parameters crucial to the phenomenon. In particular we aim to study the influence of electromagnetic fields on the system, in line with Prof Luc Montagnier’s recent results.

  1. Montagnier, L., Aïssa, J., Ferris, S., Montagnier, J.-L. & Lavalléee, C. Electromagnetic signals are produced by aqueous nanostructures derived from bacterial DNA sequences. Interdiscip. Sci. Comput. Life Sci. 2009, 1, 81–90. | Pubmed
  2. Montagnier, L. et al. DNA waves and water. J. Phys. Conf. Ser. 306, 012007 (2011). | Link
  3. Davenas E, et al. Human basophil degranulation triggered by very dilute antiserum against IgE. Nature. 1988 333(6176):816-8. | Pubmed
  4. Witt CM, Bluth M, Albrecht H, Weisshuhn TE, Baumgartner S, Willich SN. The in vitro evidence for an effect of high homeopathic potencies–a systematic review of the literature. Complement Ther Med. 2007 Jun;15(2):128-38. | Pubmed

Lead researcher

Alexander Tournier BSc DIC MASt Cantab PhD

Dr Tournier studied physics at Imperial College, London, and theoretical physics at the University of Cambridge. He wrote his PhD on the biophysics of water-protein interactions at the University of Heidelberg, Germany. For the last 10 years he has been conducting interdisciplinary research at the boundaries between mathematics, physics and biology, as an independent researcher for Cancer Research UK (5th institute worldwide for molecular biology).

Why is this project important?

Confirming the existence of structured phase of water would have considerable ramifications not only for homeopathy, but could also lead to completely novel therapeutic and diagnostic techniques. 

Dr Alexander Tournier PhD

https://www.hri-research.org/hri-research/how-do-homeopathic-medicines-work/water-research-laboratory/

Prevention of swine flu — Is homeopathy the answer? Debjani Arora Mar 09, 2015 at 11:07 am

With swine flu claiming lives at an alarming rate, death toll reaching a shocking 1300 across the country, it becomes clear that prevention is better than cure. But the sad part is many fall prey to rumours and quacks while looking for preventive measures to be safe and healthy. However, if one resents the conventional form of treatment, homeopathy stands to be a safe and wise option to follow. Moreover, it stands to be the second largest system of medicine in India. Here are 10 tips every parent should follow to keep children safe from swine flu. ‘It is a safe method of treatment with almost no side effects. The advantage of homeopathy drug is such that apart from taking care of the main symptoms, it also helps in dealing with other problems in a subtle way. So if one patient is given doses for say gastric problem, the same drug could also help in treating other minor issues of the body and build immunity. Going the homeopathy way is a safe and secure method for anyone who is looking for prevention from swine flu,’ informs Dr Bhavi Mody, Vrudhi Homeopathy and Wellness Centre, Mumbai. Here is how you can build immunity to save yourself from a bout of swine flu. 

Can homeopathy be as effective in treating swine flu as the conventional form of medication?

A study conducted by the Central Council for Research in Homeopathy from September 2009 to February 2010 pointed out that homeopathy drugs, when used to treat patients suffering from symptoms of swine flu, showed effective results in treating them. ‘In the discipline of homeopathy, when there is an outbreak of an epidemic, the few main symptoms are taken into consideration along with the major drugs that could treat the same. With swine flu, it was observed that the drug ARS. alb. 30 stood effective in both, treating and preventing a bout of swine flu,’ informs Dr Bhavi. The study also indicated that the drug could treat 80 percent of the symptoms of the flu effectively. Here are 10 facts about swine flu you need to know.

Moreover, the Indian Department of AYUSH (alternative systems) suggests use of the homeopathic medicine ARS. alb. 30, also known as Arsenic alba 30; one dose for three consecutive days as prevention for Swine flu. Here are the symptoms of swine flu that you need to be aware off.

So is homeopathy a better approach for preventing swine flu?

‘Homeopathy drugs don’t just treat the symptoms of the ailment but act on the psycho-neuron-axis of the brain, helping in building immunity and improving overall well-being. So if a patient has been following a homeopathy treatment for some other illness, his immunity is already been taken care of and would not need the said drug to fight swine flu,’ says Bhavi. Here is the answer to an important question — Is swine flu curable? 

However, for others who wish to take adequate prevention to ward off a viral attack, taking homeopathy pills, prescribed by a practitioner, can help. Remember, it is advised not to take homeopathy pills without proper consultation. As with homeopathy, all drugs are not suitable for everyone. ‘Homeopathy is a line of medicine where drugs are prescribed after taking into account the patient’s history, other signs and symptoms, apart from the existing symptoms or illness. It is a long painstaking process, so it is better to see a doctor rather than self-treat,’ says Dr Bhavi. Here is what you should know how life treats one after recovering from swine flu.

When should one turn to homeopathy?

One can take help of homeopathy treatment or use it for preventive measures at any point in time. However, keeping in mind the swine flu epidemic, it is better to reach to your practitioner soon after you see the symptoms – persistent cold, cough, high fever, etc. ‘When taken on time or soon after the symptoms of flu are noticed, homeopathy drugs can help fight swine flu and put one on the road to recovery effectively,’ says Dr Bhavi.

Image source: Getty Images

http://www.thehealthsite.com/news/homeopathy-for-swine-flu-is-homeopathy-the-answer-da0315/

GlaxoSmithKline Fined $488.8M for 'Massive Bribery Network'

Friday, September 19, 2014

China has fined the British pharmaceuticals giant GlaxoSmithKline (GSK) $488.8 million (3 billion Yuan) for a "massive bribery network" to get doctors and hospitals to use its products. Five former employees were sentenced to two to four years in jail, but ordered deported instead of imprisoned, according to state news agency Xinhua today.

The guilty verdict was delivered after a one day closed door trail in Changsha, the capital city of Hunan province. The fine was the biggest ever imposed by a Chinese court.

The court gave Mark Reilly, former head of GSK Chinese operations, a three-year prison sentence with a four-year reprieve, which meant he is set to be deported instead of serving his time in a Chinese jail. His co-defendants received two to four years prison sentences with reprieves.

Reilly was accused of operating a "massive bribery network" in May. The police said it is believed Reilly authorized his salespeople to pay doctors, hospital officials and health institutions to use GSK's products since 2009.

Chinese authorities first announced the investigation on GSK in July 2013. The police said the company had funneled up to 3 billion Yuan to travel agencies to facilitate bribes to doctors and officials. The money was the exact amount of the fine.

Throughout 2012 a stream of anonymous emails alleging bribery authorized by senior staff at GSK were sent to Chinese regulators, according to media reports. Atthe beginning of 2013, the anonymous emails began to arrive at GSK headquarter in London, along with a sex tape of Mark Reilly and his Chinese girlfriend, according to media reports.

The charges claim that GSK hired Shanghai-based investigator Peter Humphrey and his American wife, Yu Yingzeng, to locate the whistleblower. The Humphreys were detained and charged with illegally obtaining phone logs, travel records and other data which then they put in a report to GSK.

GSK released a statement of apologies to the Chinese government and people on its website.

"GSK Plc has reflected deeply and learned from its mistakes, has taken steps to comprehensively rectify the issues identified at the operations of GSKCI, and must work hard to regain the trust of the Chinese people," the statement said.

The statement also said future commitments include investment in Chinese science, improved access of its products in both city and rural areas across the country through greater expansion of production and flexible pricing.

Taking bribery from drug companies and over prescribing medicine to patients is a common hidden rule among doctors in China. It is not uncommon for patients give doctors red envelopes with cash as a blunt plea for them to do a good job on surgeries.

(Copyright ©2015 ABC News Internet Ventures.)

http://abc7chicago.com/316390/

Taking Note - The Editorial Page Editor's Blog: Facts & Figures: Vaccines Under Fire By The Editors March 6, 2015 12:30 New York Times

Americans are less likely to say vaccination is “extremely important” than they were in 2001, according to a poll released Friday. They are also much more likely to have heard about disadvantages of vaccines — 30 percent said they’d heard “a great deal” about such disadvantages, up from 15 percent in 2001.

A slight majority of Americans, 54%, say it is extremely important that parents get their children vaccinated, down from the 64% who held this belief 14 years ago. Another 30% call it ‘very important’ — unchanged from 2001. The rest, 15%, consider it ‘somewhat,’ ‘not very’ or ‘not at all important,’ up from 2001.

These results, based on interviews conducted Feb. 28-March 1 on Gallup Daily tracking, follow a relatively large measles outbreak in the U.S. stemming from pockets of unvaccinated children. This outbreak called attention to the continuing controversy over the possibly serious side effects of vaccines, a hypothesis advanced by some anti-vaccine activists, but vigorously denied by most doctors and scientists.

http://takingnote.blogs.nytimes.com/2015/03/06/facts-figures-vaccines-under-fire/?ref=opinion&_r=0

March 2015 Settlements in Vaccine Court: 117 Vaccine Injuries and Deaths

by Brian ShilhavyHealth Impact News Editor

The Depart of Justice issues a report on vaccine injuries and deaths every quarter to the Advisory Commission on Childhood Vaccines [1]. This March 5, 2015 report states that there were 117 cases for vaccine injuries and deaths compensated from 11/16/2014 to 2/15/2015.

92 of the settlements were listed in the report, giving the name of the vaccines, the injury, and the amount of time the case was pending before settlement. Five of those settlements were for deaths linked to vaccines, with three deaths related to the flu shot. 73 of the 92 settlements were for injuries and deaths due to the flu shot, and the majority of flu shot injuries were for Guillain-Barré Syndrome.

These quarterly reports on vaccine injuries and death settlements from the U.S. vaccine court are seldom, if ever, reported in the mainstream media. We report them here at Health Impact News [2]. Here is the March 5, 2015 report:

DOJ-report-vaccine-injuries-deaths-march-2015-1 [3]DOJ-report-vaccine-injuries-deaths-march-2015-2 [4]DOJ-report-vaccine-injuries-deaths-march-2015-3 [5]DOJ-report-vaccine-injuries-deaths-march-2015-4 [6]DOJ-report-vaccine-injuries-deaths-march-2015-5 [7]DOJ-report-vaccine-injuries-deaths-march-2015-6 [8]DOJ-report-vaccine-injuries-deaths-march-2015-7 [9]DOJ-report-vaccine-injuries-deaths-march-2015-8 [10]DOJ-report-vaccine-injuries-deaths-march-2015-9 [11]DOJ-report-vaccine-injuries-deaths-march-2015-10 [12]

 Most of the U.S. Public is Unaware of the Vaccine Court

the-vaccine-court [13]

In November of 2014 the Government Accounting Office (GAO)  issued the first report [14] on America’s “Vaccine Court,” known as the National Vaccine Injury Compensation Program (NVICP), in almost 15 years. Most citizens of the United States are not even aware that there is something called the National Vaccine Injury Compensation Program, and that if you suffer harm or death due to a vaccine, that you cannot sue the manufacturer of the vaccine, but you must sue the Federal Government and try to obtain compensation from the Vaccine Injury Compensation Trust Fund, which is funded by taxes paid on vaccines.

The November 2014 GAO report criticized the government for not making the public more aware that this program exists, and that there are funds available for vaccine injuries. Therefore, the settlements represented by vaccine injuries and deaths included in the DOJ report probably represent a small fraction of the actual vaccine injuries and deaths occurring in America today.

The Federal Vaccine Court is Not Helping Victims of Vaccine Injuries and Vaccine Deaths

But even for those families and individuals who are aware of the NVICP, fighting a legal battle that can take years to get access to the funds ensures that many who do file claims never get any of the funds reserved for vaccine injuries. That fund, the Vaccine Injury Compensation Trust Fund, is currently over $3.5 billion, largely because the U.S. Government refuses to even hear cases related to autism which would quickly deplete the fund. (See: How the Government has Earned $3.5 BILLION from the Claim that Vaccines Don’t Cause Autism [15].)

Wayne Rohde, author of the book The Vaccine Court: The Dark Truth of America’s Vaccine Injury Compensation Program [13], explains how the NVICP is no longer a viable justice venue for the vaccine injured as Congress intended it to be. (See: GAO Report on Vaccine Court Reveals Vaccine Injured Victims Not Being Helped [16].)

Lies, Fraud, and Corruption Mar U.S. Vaccine Policy

The unified message presented by the U.S. mainstream media and certain government agencies is that vaccines are safe.

This is a lie. Vaccines are dangerous. People are injured and killed by vaccines, and the quarterly reports from the DOJ, which probably reflects a very small percentage of the actual cases, clearly reflect that inherent danger.

So many people were being injured and killed by vaccines in the 1980s, that the pharmaceutical companies petitioned Congress to pass legislation giving them legal immunity from cases in civil court. They basically blackmailed Congress by threatening to get out of the vaccine business if such legislation was not passed.

Congress obliged in 1986, and today we have the NVICP, while new vaccines entering this “protected” and “guaranteed” market have soared. The largest purchaser of vaccines is the CDC, purchasing over $4 billion worth of vaccines a year [17].

In addition, the U.S. Government holds patents on some vaccines, and earns royalties on them [18], such as the Gardasil vaccine. Julie Gerberding was in charge of the CDC from 2002 to 2009, which includes the years the FDA approved Gardasil as a vaccine. Soon after she took over the CDC, she ties to the vaccine industry [19].

Gerberding resigned from the CDC on January 20, 2009, and is now the president of Merck’s Vaccine division, a 5 billion dollar a year operation, and the supplier of the largest number of vaccines the CDC recommends (article here [20]).

In 2014 Dr. William Thompson, a senior epidemiologist at the CDC who co-authored and published research on the MMR vaccine for the CDC back in 2004, made the decision to become a whistleblower and reveal data that was concealed by the CDC linking the MMR vaccine to autism among African American boys. In addition, Merck has been involved in a long federal lawsuit with allegations of fraud over the mumps portion of the MMR vaccine, in a case filed back in 2010 by two whistleblowers, virologists who worked for Merck. Merck has apparently tried hard to get this case thrown out of court, and keep this news out of the media, but late in 2014 a federal judge finally ruled that the case is to move forward. (See: Why is the Mainstream Media Ignoring Measles Vaccine Fraud Cases [21]?)

Conclusion: Do Not Trust what the Government Says About Vaccines

The U.S. government has massive conflicts of interest where it concerns policies related to the vaccine industry. Before you make a potential life-changing decision for you or your children by agreeing to be vaccinated, do your own research. The government cannot be trusted on vaccine matters, and the mainstream media and many doctors are also not doing their own research related to the vaccine industry. Be informed and educated regarding vaccines, before you become a statistic among the vaccine injured and dead.

Previous DOJ reports on vaccine injuries and deaths [2].

 

Saying NO To Vaccines By Dr. Sherri Tenpenny You have legal options!

saying no to vaccines [22]

http://vaccineimpact.com/2015/march-2015-settlements-in-vaccine-court-117-vaccine-injuries-and-deaths/print/

Evolution of multiple sclerosis in France since the beginning of hepatitis B vaccination

Evolution of multiple sclerosis in France since the beginning of hepatitis B vaccination

Abstract

Since the implementation of the mass vaccination campaign against hepatitis B in France, the appearance of multiple sclerosis, sometimes occurring in the aftermath of vaccinations, led to the publication of epidemiological international studies. This was also justified by the sharp increase in the annual incidence of multiple sclerosis reported to the French health insurance in the mid-1990s. Almost 20 years later, a retrospective reflection can be sketched from these official data and also from the national pharmacovigilance agency. Statistical data from these latter sources seem to show a significant correlation between the number of hepatitis B vaccinations performed and the declaration to the pharmacovigilance of multiple sclerosis occurring between 1 and 2 years later. The application of the Hill’s criteria to these data indicates that the correlation between hepatitis B vaccine and multiple sclerosis may be causal.

Keywords: Hepatitis B vaccine, Multiple sclerosis, Demyelinating disease, Pharmacovigilance, Vaccine adverse events

Introduction

The first doubts regarding vaccines as a possible cause or exacerbation of multiple sclerosis (MS) were formulated by Miller more than half century ago [1]. Hepatitis B (HB) vaccine has been the subject of greatest concern, especially in France where mass HB vaccine administration was performed in a short time. In 1992, the World Health Organization (WHO) recommended undertaking a universal HB vaccination of all young infants in order to eradicate the HB virus. WHO explained that the teenagers’ vaccination could also be used in addition to or instead of the vaccination of young children in low-endemic countries. In 1994, the French health authorities launched a national vaccination campaign of all pupils in the first year of secondary school. The following year, HB vaccine was added to the national immunization program for all young babies and preteenagers. This intensive campaign had quickly exceeded its expected targets by also encouraging the adult population to be mass-vaccinated, whereas the vaccination of the infants remained less significant. This resulted in an unprecedented “wave” of immunization in adults, with 20 million French individuals vaccinated against HB, concentrated in 4 years, from 1994 to 1997.

MS cases in some vaccinated adults were rapidly notified to the French national pharmacovigilance system (ANSM), triggering investigation by this agency. This inquiry, started in 1994, was therefore already underway when French media revealed possible occurrence of post-immunization MS in 1998. This year, French health authorities abruptly terminated routine school-based vaccination of preteens, and adult HB vaccination began to be less widespread.

Several epidemiological studies have been evaluating the correlation between HB vaccination and MS in adults for a decade. Most of these publications found the absence of a link [26] or a slightly increased risk, but not sufficiently significant on the statistical level [79]. However, different opinions have also been formulated. A study aiming at quantifying underreporting in Fourrier’s article [8] was conducted by D. Costagliola on request of the French pharmacovigilance. This unpublished study showed by the “capture–recapture” method that the real number of MS cases linked to HB vaccine was 2–2.5 higher than the officially registered number [10]. This additional calculation makes Fourrier’s publication [8] clearly significant. Another case–control epidemiological study was conducted to evaluate serious post-vaccination adverse events registered in the United States through a spontaneous reporting system in the VAERS database. Adults receiving HB immunization had significantly increased odds ratios (OR) for MS (OR 5.2; CI 1.9–20) in comparison with an age-, sex-, and vaccine year-matched unexposed tetanus-containing vaccine group [11]. A Hernan’s paper, based on a case–control study in the United Kingdom within the General Practice Research Database (GPRD), found an increased risk (OR 3.1; CI 1.5–6.3) of MS within the 3 years following HB immunization [12]. In the same way, a French study on demyelination in childhood [13] showed that Engérix B® vaccine administration was associated with an increased trend of confirmed MS after 3 years (OR 2.77; CI 1.23–6.24).

On these grounds, we compared temporal HB vaccine dose distribution and MS occurrence in the French population, using the official data collected by the French pharmacovigilance system (ANSM) and the national health insurance (CNAM). The results confirmed, at the global population level, a significant correlation between the number of immunizations and both the number of MS cases declared to the pharmacovigilance system 1–2 years later and an overall increase in identified MS cases in the country.

Materials and methods

Databases

We compared data from two independent national databases: the National Health Service database (CNAM) [14] and the French pharmacovigilance system (ANSM) [15].

CNAM

The French general insurance provides each year the number of new cases of MS in which care is fully supported. These data are available online on the Web site of the CNAM [14]. The concerned population represents a very large majority of people covered by the healthcare system (83 % of the French population in 1996).

ANSM

This organization identifies spontaneous adverse event reports emerged in the aftermath of vaccinations since the beginning of the establishment of HB immunization (1981). The most common diseases reported were neurological damages of myelin, known under the generic term of demyelinating diseases. This condition is clinically called MS when at least two attacks of demyelination repeat themselves. When the neurological disorder remains single, without temporal or spatial diffusion, we speak of central nervous system demyelination.

The French pharmacovigilance is based on “spontaneous reporting” of adverse drug reactions. This allows the establishment of a possible relationship as well as the imputability to generate alerts. However, this system underestimates the real frequency of adverse reactions (1–10 % of severe side effects are reported) [16].

On the other hand, from 1997, the notification by REVAHB, the association of victims of HB vaccine, allowed the completion of these spontaneous reports of potential side effects. Since its inception, this association has been able to transmit more than 2,000 files of individuals who have experienced a neurological problem of post-vaccine demyelination. However, about a third of these files are not used by the French pharmacovigilance (classified as “not documented”) when the physician does not answer to the questionnaire which ANSM sends him for confirming the diagnosis. Of course, this rate of not documented files is an obvious factor of underreporting.

Statistical analyses

We used the R statistical software to compute correlations and perform linear regressions.

Results

CNAM data analysis

The number of MS was very stable, about 2,500 new cases each year until 1993. The following years, and especially since 1996, a progressive increase in the number of new MS reported to the Health Insurance occurred. This figure increased to about 4,500 cases in 2003 and remains steady since.

The annual incidence was 5.3/105 in 1993 and increased to 8.7/105 insured people a decade later (Fig. 1), which translates into a 65 % increase in incidence over the 10-year period. These figures are consistent with epidemiological data published in this country. Indeed, the incidence of MS in France was estimated at around 4.3/105 inhabitants in the years 1993–1997 from a representative sample of the Burgundy region [17]. It was reassessed by the same team at a rate between 7.6 and 8.8/105 inhabitants for the period 2001–2007, from French CNAM data [18].

Fig. 1

Evolution of annual incidence rate of MS supported by the French health insurance system (CNAM), comparison with annual sales of Hepatitis B (HB) vaccine in France (1990–2009)

Epidemiological studies measuring prevalence of this disease provide an increase in the same magnitude. This figure was 40/105 insured people in 1994, at the beginning of the mass vaccination campaign [19]. It increases rapidly until 95/105 12 years later [20].

ANSM data analysis

Since the beginning of practicing HB vaccination in France until December 31, 2010, ANSM has registered 1,650 demyelinating diseases including 1,418 MS. These data are available online on the Web site of ANSM in the French national commission for pharmacovigilance of September 27, 2011 [15]. When you draw a distribution curve of MS reported each year to ANSM in the aftermath of a vaccine injection, we see that this distribution is neither linear nor regular, far from it (Fig. 2). There is a huge peak of reported MS culminating in the years 1995 (229 reports) and 1996 (246 reports). This peak of post-vaccine neurological disorders during the period 1994–1998 corresponds, with an interval of one year, to the beginning of the campaign and intense promotion of the HB vaccination in France (culminating in the year 1995 with about 23 million vaccine doses sold).

Fig. 2

Sales of Hepatitis B (HB) vaccine every year in France, comparison with report of post-vaccine MS to the national pharmacovigilance agency (ANSM) (1984–2010)

We studied the correlation between MS data (Y) and vaccinations data (X). This correlation is high and maximum (0.9365863) between the number of vaccines sold at t time (called Xt) and the number of MS occurring the following year, t + 1 (called Yt + 1). There is also a high correlation (0.7350417) between vaccines sold at t time (Xt) and the number of reported MS 2 years later (called Yt + 2).

If we model this relationship in a linear fashion without constant (since in the absence of vaccination there are no MS cases registered by pharmacovigilance), the best model is one where the coefficient of determination adjusted R2 is the highest (i.e., = 0.9497).

This model is defined by the relation: Yt + 2 = ß1Xt + ß2Xt + 1 + ß3Xt + 2

The series of sold vaccines at t time (Xt) and 1 year later (Xt + 1) have a significant influence (p = 0.00106 for Xt and 0.02491 for Xt + 1) on the number of reported MS at t + 2 years (Yt + 2), i.e., 2 years later. But we cannot say whether the number of vaccines sold in year t + 2 (Xt + 2) has a significant influence (p = 0.07014). Graphically, this relation is also the model that best fits the peak of reported MS to ANSM.

It is difficult to adjust the MS data after year 2002. There is then a notable difference between the theoretical series (models) and the actual series. This can be explained by the fact that the number of vaccinations mentioned by ANSM became less precise figures, rounded and approximate. In addition, since 1999, the immunization target has been focused on young children. Adult vaccination has become uncommon, reserved only for high-risk groups. Finally, the number of MS reported to pharmacovigilance has arguably become more and more underestimated over the years. The problem of the emergence of post-vaccine MS had been widely publicized in the years 1996–1999. Thereafter, over the years, this problem has been trivialized or forgotten. Since this period, underreporting became more important. People who have been victims of adverse events have not necessarily reminded the physician of the injection of a HB vaccine some weeks or months before.

Discussion

Are we able to establish a relation between these results and the Hill’s criteria [21]? Is there a causal relationship between the HB vaccination and the incidence of MS in France? The Hill’s criteria for causation include nine items detailed in Table 1. We will detail now the most important criteria in the text, the other being a simple bibliographic reference mentioned in this table.

Table 1

Study of Hill’s criteria

The current study satisfies the first criterion. The association is highly statistically significant between reported MS (Yt + 2) to pharmacovigilance and the series of HB vaccines that were sold 1 and 2 years before (p < 0.01 for sold vaccines 2 years before (Xt) and p < 0.05 for sold vaccines 1 year before (Xt + 1); adjusted R2 = 0.9497). Although it is possible to demonstrate here a statistical relationship between the number of sold vaccines and MS reported to the pharmacovigilance, it is not enough to affirm an absolute causality. This is a strong signal that requires further epidemiological studies.

The positive and statistically significant correlation between HB vaccine exposure and reported MS incidence is consistently observed in different places, circumstances, and times (criterion 2).

First, this result is consistent with the Hernan’s case–control study [12] that found in the British population an increased risk of MS (OR 3.1; CI 1.5–6.3) in the 3 years following HB vaccination. Moreover, in this same study, the risk was greater when the last immunization took place within the second or third years before first symptoms of MS (OR 4.1; CI 1.3–13.6).

The results of the case–control study by Geier [11] in USA are also consistent with the French pharmacovigilance data. There is a very significant change in the risk of developing MS after HB vaccine in adults in the VAERS database (OR 5.2, p < 0.0003; CI 1.9–20).

The Costagiola’s study [10] found underreporting of post-vaccine reported MS during the observation period (1994–1996) of an epidemiological study requested by French pharmacovigilance [9]. The combination of these two studies suggests a real number of cases significantly higher (RR = 1.66) than the expected number of MS during the 3 years of the collection.

Most publications where there is no link between HB vaccination and the onset of MS [25] received grants from pharmaceutical industry. Other criticism that can be raised for some of these negative case–control studies is the limited period (2–24 months) of their survey [4, 79]. Moreover, the Hernan’s publication [12] shows also a negative result (OR 1.8; CI 0.5–6.3) for a period of 1 year and becomes significant between 2 and 3 years of follow-up after HB immunization.

The case–control study nested in the Nurses’ Health by Asherio [4] presents several biases. The vaccination status was obtained retrospectively like the date of first symptoms of the disease assessed by questionnaires. This process may cause selection bias leading to a downwardly biased OR as the specific (nurses) selected population [26].

At last, a meta-analysis [27], based on six epidemiological case–control studies [47, 11, 12], did not find significant change in the risk of developing MS after HB vaccine in adults (OR 0.92; CI 0.84–1.004). This paper can also be criticized. Strangely, the statistical computing of this meta-analysis attributes a non-significant value to the Hernan’ study [12], with an OR 1 (CI 0.5–2.1) by using the cases’ date of diagnosis as the index date instead of the date of first symptoms as the author does. But as Hernan wrote [12], “the use of dates that are posterior to the true date of first symptoms may cause a downward bias of the OR for acute exposures such as vaccinations”. In addition, the most significant study by Geier [11] is removed, being regarded as a “source of heterogeneity”. So, withdrawal of a positive study and changing the result of another one more easily allows a negative outcome.

Generally speaking, we know that a low risk of adverse post-vaccination cannot be demonstrated by studies of low statistical power with small numbers of exposed people. Therefore, results in a population of over 20 million vaccinated people should attract attention and require further epidemiologic studies. Moreover, studies with a short period of post-vaccination monitoring are inadequate because they do not take into account the long biopersistence of immunostimulatory vaccine compounds (such as aluminum hydroxide) in the body. In this, vaccines derogate from the rule generally used for side effects of drugs.

The temporal relationship (criterion 4) clearly exists here. The annual incidence of MS recorded by the French insurance was stable about 5.5/105 until 1995. It rose sharply in 1996 to stabilize around 8/105 from 1998. But this sharp increase (65 %) closely follows a major peak in the number of vaccines sold between 1995 and 1997 in France (Fig. 1). The number of MS occurring in the aftermath of a HB vaccination reported to the French pharmacovigilance almost draws the same peak with a delay between 1 and 2 years (Fig. 2). Moreover, some papers report observations of MS relapses triggered by repeated injections of HB vaccine [28, 29].

The official explanations of the increase in this incidence are twofold, first a better screening of MS whose diagnosis has been made easier and faster by using radiological data provided by MRI. This is a dubious explanation. This new radiological technique has begun to develop gradually in French hospitals in 1990 and thus before the obvious increase in the recruitment of MS by French national insurance (1996). Otherwise, if this earlier diagnosis was really so important in the increased incidence of MS, we should have observed in France a decrease in the average age of newly diagnosed cases. And this rejuvenation was not observed [30].

The second factor involves the change in treatment protocol of this period with the introduction of treatment with interferon-beta in 1995, an innovative and very expensive drug that prompted physicians to quickly seek a total care by French health insurance. In 2004, the emergence of a new drug (glatiramer), indicated for the most common form of MS (relapsing–remitting), has not been followed by an increase in cases registered by CNAM that year and the following. The incidence remained the same. This explanation cannot alone explain a so rapid and significant increase (65 % over 4 years) in the incidence of a disease like MS.

A third factor must be considered in such a sudden increase in MS incidence. So the changing of an environmental etiological factor must be taken into account seriously. This therefore appears to be the case for the question of the potential role of HB vaccination carried out in France for a short time and in a massive way, about 20 million people concentrated in 4 years. It is interesting to compare these figures with those countries where routine vaccination has not been recommended. In Norway, the incidence of MS is higher than in France in the early 1990 s (8.7/105 between 1990 and 1995). Then, it decreases slightly in subsequent years (7.2/105 from 1996 to 2000) [31]. In the county of Värmland (Sweden), the incidence of MS has remained similar (6.4/105) during the periods 1991–1995 and 1996–2000 [32].

Specificity (criterion 3) is likely for a very specific population at a specific site and disease. This is not applicable to diseases such as MS. Genetic risk (HLA-DR2) and environmental factors (vitamin D insufficiency) or infectious factors (Epstein–Barr virus, endogenous retroviruses) are clearly involved in the occurrence of MS although its etiology and pathophysiology are not completely understood. These other environmental and genetic factors may have contributed to the raise in MS incidence and should be mentioned.

Biological plausibility (criterion 6): A plausible mechanism between cause and effect is helpful. Are there explanations regarding plausible mechanisms by which vaccines and particularly this vaccine may induce harm? This issue has been extensively studied in recent years. Various aspects of the causal and temporal interactions between vaccines and autoimmune phenomena are known, as well as the possible mechanisms by which different components of vaccines might induce autoimmunity [33]. A first hypothesis could be the similarity between the protein S (used in the vaccine against HB) and some myelin proteins such as PLP (proteolipid proteins) [34]. Another interesting track would be contamination by minor HB virus polymerase proteins. And we know that HB virus polymerase shares significant amino acid similarities with the human MBP (myelin basic protein) [35]. This process is called molecular mimicry: a foreign antigen that shares sequence or structural similarities with self-antigens.

Another runway about biological plausibility is to take into account the metabolism of vaccine adjuvants in the human body. The long-term persistence of aluminum adjuvant at the site of vaccine injection is now well established [36]. Furthermore, transferring of aluminum particles from muscle to brain is demonstrated in animals [37]. A new syndrome entitled ASIA, “Autoimmune (Auto-inflammatory) Syndrome Induced by Adjuvants”, was recently described, grouping four similar illnesses [38]. These diseases (siliconosis, the Gulf war syndrome, the macrophagic myofasciitis syndrome and post-vaccination phenomena) were linked with previous exposure to an immune adjuvant (silicone, aluminum salts). In another publication, the same authors found common clinical characteristics of the ASIA criteria among 93 patients diagnosed with immune-mediated conditions post-HB vaccination, suggesting a common denominator in these diseases [39].

Conclusions

The figures available in France thus show a definite statistical signal in favor of a causal link between the HB vaccine event and the apparition of MS with a maximum correlation in the 2 years following immunization. The impact of other factors (new use of MRI, beginning of interferon-beta) is probably associated. The weakness of this study is its retrospective nature and therefore subject to bias of notoriety. Its strength is that it is based on indisputable official data on large numbers and during about 12 years. The appearance of a spectacular “vaccine wave” in France has remained the only one in its kind. The intensive lobbying carried out in the years 1994–1997 led to concentrate as many vaccinated people as possible in the shortest period of time. This particularity is perhaps the explanation of the emergence of the problem of post-vaccine MS, especially recorded in this country. The low overall frequency of this adverse effect, not measurable in most epidemiological studies, here becomes more obvious because of a kind of involuntary very large scale experiment carried out on a third of the French population. All this is expected to require further epidemiological studies, particularly from the French health insurance data. Indeed, CNAM has information on millions of insured persons for many years that would be usable if we could more easily access it.

Acknowledgments

The author thanks Mr. A. Sesboüe (Department of Statistics, Caen University, France) a lot for his statistical interpretation. He also gratefully acknowledges Pr. C. Exley (Bioinorganic Chemistry Laboratory, Keele University, Staffordshire, UK) and Pr. R. K. Gherardi (Department of Pathology, Creteil University Hospital, France) for their judicious rewriting.

Conflict of interest

The author declares that he has no conflict of interest.

Abbreviations

ANSM
Agence nationale de sécurité du médicament et des produits de santé in French
CI
Confidence interval
CNAM
Caisse nationale d’assurance maladie in French
GPRD
General Practice Research Database
HB
Hepatitis B
MBP
Myelin basic protein
MRI
Magnetic resonance imaging
MS
Multiple sclerosis
OR
Odds ratio
p
p value
PLP
Proteolipid proteins
R2
Coefficient of determination R-squared
RR
Relative risk
REVAHB
Réseau vaccin hépatite B in French
VAERS
Vaccine Adverse Events Reporting System
WHO
World Health Organization

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266455/

North & South and Homeopathy – Truth or Fiction?

The July 2012 issue of the New Zealand magazine North & South proudly bore the title for its cover story: “Do you believe in magic? The truth about alternative medicine.” The issue included an article which displayed with equal pride the title “Homeopathy – trick or treatment”. The byline to this article stated: “Homeopaths claim their formulas have “energetic powers”. Scientists say the only power in these potions is the placebo effect.”

Clive Stuart, a Tauranga homeopath, complained to the Press Council that the article and accompanying editorial were highly derogatory, inaccurate and misleading. The Press Council upheld the complaint (see www.presscouncil.org.nz/display_ruling.php?case_number=2320).

Mr Stuart’s complaint was supported by a detailed critical analysis of a key article, written by Dr David St George, a clinical epidemiologist. The key article was a meta-analysis of 110 homeopathy clinical trials and 110 conventional medical clinical trials, published in the Lancet in 2005. Sceptics often use this article to bolster up their belief that homeopathy is nothing more than a placebo. However, the Lancet article has already been challenged in the international scientific literature. Critics say that it has been subjected to selection bias through the process that the authors used to identify a subset of the clinical trials for more detailed analysis. The article’s conclusions are based on the subset analysis, but the selection bias in their methodology undermines the validity of their conclusions.

The critical analysis which supported Mr Stuart’s complaint doesn’t therefore say anything new. All of it has previously been said in the international scientific literature. What now follows is an edited version of the analysis.

Untruthful statements in “Homeopathy – Trick or Treatment?”

There are two key statements in this article, which are both untrue:

“….homeopathic remedies have failed every randomised, evidence-based scientific study seeking to verify their claims of healing powers.”

“…there is no scientific evidence of homeopathy’s efficacy.”

These statements are absolute claims about the absence of any scientific evidence and, as such, they are factually incorrect. There are indeed published “randomised, evidence-based scientific studies” which demonstrate the efficacy of homeopathy, contrary to the article’s claim.

The article’s claims appear to arise from a study published in the Lancet in 2005: “Are the clinical effects of homeopathy placebo effects? Comparative study of placebo-controlled trials of homeopathy and allopathy”, by Shang et al. This study is regularly quoted by critics of homeopathy as the definitive scientific answer to the question of whether or not homeopathy is anything more than a placebo effect.

Shang et al set out to prove that there is no scientific evidence of any therapeutic benefit from homeopathy beyond the placebo effect. The conclusion that they reached was that their findings do substantiate their a priori hypothesis of homeopathy being nothing more than a placebo effect. However, critics of Shang et al’s methodology have pointed out that there are inherent biases and limitations in their analysis. A more rigorous analysis of Shang et al’s data shows that their hypothesis cannot be substantiated.

The Shang et al study is important to understand because it sheds light the current debate about scientific evidence and homeopathy. It helps to clarify why absolute claims (such as those outlined in North & South) are being erroneously made about the absence of scientific evidence of efficacy, when in fact such evidence exists. This study therefore warrants a more detailed exploration.

The Shang et al study is a meta-analysis of 110 published placebo-controlled trials of homeopathy, compared with 110 published placebo-controlled trials of conventional medical drug treatment.

The first point to emphasise is that Shang et al’s own conclusions are not as absolute as North & South’s statements. Their interpretation section (in the summary of their published paper) says that their analysis indicated that “there was weak evidence for a specific effect of homeopathic remedies, but strong evidence for specific effects of conventional interventions.” Note that they did not say there was “no evidence” for a specific effect of homeopathic remedies, but only “weak evidence”. North & South’s absolute claim of no evidence (the second statement above), therefore, is not supported by this study.

Secondly, the majority of the 110 homeopathy trials that were included in the study are “randomised, evidence-based scientific studies” (to use North & South’s phrase). Some of them may well be considered to be lower quality studies, but, nevertheless, they still include “randomised, evidence-based scientific studies” which have clearly demonstrated evidence of a therapeutic benefit beyond the placebo effect. North & South’s first statement (above) is therefore factually incorrect and misleading.

Thirdly, the real debate is not about whether or not there are any scientific studies demonstrating homeopathy’s therapeutic benefit, because there are quite a number of such published scientific studies which do show a therapeutic benefit. The debate is somewhat different from this. It is about whether or not the published scientific studies that do clearly demonstrate homeopathy’s therapeutic benefits are of acceptable methodological quality.

What the critics of homeopathy argue is that these scientific studies are methodologically flawed and must therefore be discounted. Indeed, this is what Shang et al tried to prove.

There is a well-known statement which summarises this position: “If the facts don’t fit the theory, then the facts must be wrong.” Homeopathy is considered by many conventional biomedical thinkers to be implausible - it cannot possibly have any therapeutic benefit. Any research which appears to show a therapeutic benefit must therefore be flawed research, which should be discredited. This is an a priori stance, based on theory and belief.

This approach is hinted at in a follow-up letter about the homeopathy article that North & South published. This is from Dr Shaun Holt of Tauranga. In this letter, he said:

“..there has never been a single, reproduced study, of an acceptable standard, showing any effect whatsoever of homeopathy in people, animals or even in a test tube.”

Note that this statement is different from North & South’s, in that Dr Holt introduces the qualifier, “an acceptable standard”. There is absolutely no doubt that there are published scientific studies showing efficacy of homeopathy. However, the ones that do show efficacy are considered by Dr Holt (and others like him) to be “of an unacceptable standard”, and must therefore all be rejected. The question is whether Dr Holt and the others who take this stance are justified in doing so, from the perspective of scientific evidence (as opposed to scientific theory or belief).

If you want to locate the published scientific studies which demonstrate the efficacy of homeopathy, you only have to read Shang et al’s study in detail, because these studies are contained within it.

Below is Figure 2 from Shang et al’s publication. This compares the 110 homeopathy trials with the 110 conventional medicine trials, using what is called a “funnel plot”. Each trial is a dot on the appropriate graph.

Homeopathy Trial Graph

The horizontal axis is the “odds ratio”, which (in simple terms) indicates the degree of benefit arising from the active treatment (whether homeopathy or conventional medicine) when compared with placebo treatment.

  • An odds ratio of 1 (indicated by the vertical dotted line) is where the active treatment equals placebo, in terms of the degree of therapeutic benefit.
  • An odds ratio to the left of the “1” (i.e., a smaller ratio than 1) indicates a therapeutic benefit from the active treatment which is greater than placebo. The further to the left the trial is positioned, the greater the benefit is from the active treatment.
  • An odds ratio to the right of the “1” indicates that placebo treatment confers a greater therapeutic benefit than the active treatment.

The vertical axis (SE) is a proxy indicator of sample size. Larger trials are towards the top of the graph and smaller trials are towards the bottom.

These figures show a very similar picture for the 110 homeopathy trials and 110 conventional medicine trials. The majority of both groups show a beneficial therapeutic effect (i.e., they are to the left of the vertical dotted line). Also, in both groups, smaller trials (in the lower part of the graph) show more beneficial treatment effects than larger trials (towards the top of the graph).

With regard to North & South’s claim of “no scientific evidence of homeopathy’s efficacy” the homeopathy graph demonstrates something different. In this overall analysis, there is scientific evidence of efficacy amongst those studies which are to the left of the vertical dotted line.

However, as I have already said, the real debate is more about whether the large number of homeopathy clinical trials which do show efficacy are of sufficient methodological quality; or whether they can be rejected as being methodologically flawed.

Shang et al therefore went a stage further in their study and attempted to identify a subset of “higher quality” homeopathy and conventional medicine studies from amongst the 220 trials.

They tried to see if restricting their analysis to only “higher quality” trials would confirm their hypothesis that homeopathy is no better than placebo.

They focused on three indicators of research methodology quality: (1) the degree of randomisation and concealment of allocation; (2) the degree of masking (“blinding”) of patients, therapists and outcome assessors as to which group individual patients were in (i.e., active treatment or placebo); and (3) the degree to which the results were analysed by intention to treat (i.e., including all patients who were randomised in the analysis, not just those who were treated and followed up to the end of the study).

Using these criteria, they produced a subset of 30 trials: 21 “higher quality” homeopathy trials and 9 “higher quality” conventional medicine trials. However, they did not publish an analysis of how the two groups compared, in terms of therapeutic benefit. Instead, they restricted their analysis to only “larger” trials amongst the thirty. Using an arbitrary definition of a “larger” trial, they ended up with a subset of only 14 trials: 8 homeopathy trials and 6 allopathic trials.

Comparing the combined results of the 8 homeopathy trials with the combined results of the 6 allopathic trials, they found that the 8 selected homeopathy trials did not demonstrate any overall therapeutic benefit beyond placebo, whereas the 6 allopathic trials did.

The overall conclusion that Shang et al published (i.e., that their findings support the notion that the clinical effects of homeopathy are placebo effects) is thus based on this “8 vs 6” comparison, not on the “110 vs 110” comparison (nor on the “21 vs 9” comparison).

At this point, it is important to emphasise that the way that Shang et al undertook the subset selection and analysis did not adequately conform to the scientific method. The study itself is a methodologically flawed study.

The “scientific method” is not just about carrying out appropriately designed experiments and analyses; it is about the entire process that is driven by your intention to prove empirically and conclusively that your scientific hypothesis is correct. Because all of us (including scientists) are prone to biases and self-deception, a scientific investigator has to establish empirical investigations that adequately remove his/her own biases towards proving that the hypothesis under investigation is correct. In other words, as a scientist, you have to be “your own worst critic” in your choice of methodology. You have to demonstrate sceptically and convincingly to others that the results you have obtained are robust, objective and not distorted by your own a priori beliefs. You have to attempt to refute your own scientific hypothesis.

In practical terms, this is done by denying your own scientific hypothesis in your research methodology. Although you start the process with a scientific hypothesis, you then adopt the position opposite from this, which is often called the “null hypothesis”. You then continue your investigation under the assumption that the null hypothesis is correct (i.e., that your scientific hypothesis is wrong) and you adhere to the null hypothesis unless and until you have overwhelming evidence to the contrary. This evidence allows you to reject the null hypothesis and accept the scientific hypothesis with a high degree of confidence.

With regard to Shang et al’s study, the starting point (i.e., the scientific hypothesis) is that homeopathy is nothing more than a placebo. The purpose of their analysis was to explicitly prove this. In Shang et al’s words:

“We assumed that the (positive) effects observed in placebo-controlled trials of homeopathy could be explained by a combination of methodological deficiencies and biased reporting. Conversely, we postulated that the same biases could not explain the effects observed in comparable placebo-controlled trials of conventional medicine.”

The authors are quite open about their a priori belief in the implausibility of homeopathic treatment, and their consequent hypothesis that any apparently positive results from placebo-controlled homeopathy trials must be false positive results, arising from flawed methodology and biased reporting.

Shang et al are entitled to adopt this belief as a scientific hypothesis. However, in order to conform to scientific methodology, they should have then taken the opposite stance; i.e., they should have become their own worst critic. They should have adopted the null hypothesis that the therapeutic benefit from homeopathy is more than a placebo.

They should then have rejected this null hypothesis only if they found overwhelming and irrefutable evidence that homeopathy was indeed a placebo. They could only have achieved this through a far more robust and critical analysis.

Putting this in another way, instead of attempting to refute their own scientific hypothesis, Shang et al carried out a subset analysis in order to find the evidence to support it. They found exactly what they were looking for, in the “8 vs 6” comparison, but they made somewhat arbitrary and subjective decisions along the way, in order to get there. Their analysis is thus a long way away from what should be expected from robust scientific research. Indeed, it has already been considered to be an example of “data dredging”; i.e. looking for what you want to find, digging deeper into the data in order to find it, without critically evaluating the validity or robustness of the methodology being used.

What Shang et al should have done (as a minimum) is a standard analytical procedure known as a “sensitivity analysis”. They should have critically tested the sensitivity of their subset selection process, to see if changing the selection criteria and threshold values that they used would have resulted in a different subset of trials with different overall results.

Fortunately, such a sensitivity analysis has been carried out (by others) and published (elsewhere). It was published in 2008 in the Journal of Clinical Epidemiology as “The conclusions on the effectiveness of homeopathy highly depend on the set of analysed trials”, by Ludtke and Rutten. The authors demonstrated that some of Shang et al’s selection criteria were somewhat arbitrary and subjective. By changing the threshold of the selection criteria, different results could be obtained, in terms of the overall therapeutic benefit of homeopathy. The authors said:

“Shang et al in their article arbitrarily defined one subset of eight trials which provided an overall negative result for homeopathy. Our article shows that the choice of other meaningful subsets could lead to the opposite conclusion.”

For example, Ludtke and Rutten found that if they changed the arbitrary criterion for a “larger” trial used by Shang et al (i.e., the largest quartile of the subset, based on a sample size N=98 or larger) to the median sample size of all homeopathy trials (i.e., N=66 or larger), the subset of homeopathy trials selected by this latter criterion showed a significant therapeutic effect in favour of homeopathy. There is no objective or meaningful a priori reason for choosing Shang et al’s definition of a “larger” trial over any other definition, and therefore no objective or meaningful reason for concluding that the “8 vs 6” comparison is the one subset to be used use in order to carry out the “definitive” comparison between homeopathy and conventional medicine.

However, just as interesting is the fact that they did not publish the comparison of the subset of “higher quality” trials that they first selected, as mentioned above (i.e., the 21 homeopathy trials versus 9 conventional medicine trials). This analysis, as demonstrated by Ludtke and Rutten, showed a statistically significant therapeutic benefit for homeopathy. It is not self- evident that Shang et al had to skip over this analysis and restrict the “definitive” analysis even further, to “larger” trials only. Other things being equal, a medium-sized study with statistically significant results cannot be rejected out of hand just because of its sample size. The statistical analysis would have taken into account the sample size.

Choosing only larger studies can also introduce other biases. For example, larger homeopathy trials tend to be based on a very different homeopathic approach from smaller homeopathic trials; e.g., using a conventional medical diagnosis to define the subjects and using the same single remedy for all subjects in the larger trials. This is an approach which classical homeopaths claim dramatically reduces the effectiveness of their treatment.

Shang et al thus appear to have adopted the “data dredging” approach (i.e., pursuing analyses until they found the answer they were looking for), rather than a truly scientific approach (i.e., attempting to refute their own hypothesis). Reaching the author’s conclusion required a subjective and somewhat arbitrary choice of subset selection criteria. A different choice would have led the authors to the opposite conclusion. Shang et al’s study does not therefore provide robust scientific evidence that homeopathy is no more than placebo.

We are therefore left with the status quo with regard to scientific evidence and homeopathy; namely that there is a large group of published placebo-controlled trials of homeopathy which demonstrate therapeutic benefit for homeopathy. The quality of these trials is just as variable as the quality of conventional medicine trials.

Those who currently reject the positive homeopathy trials as being of an unacceptable methodological standard are thus doing so more because of their a priori belief that homeopathy can be nothing more than placebo, rather than from the basis of an objective, unbiased, rigorous analysis of scientific evidence.

In conclusion, this analysis supports the opinion that the article is one-sided; is based on a factually incorrect and misleading understanding of the nature of the scientific evidence concerning homeopathy’s efficacy; and is thus inaccurate, unfair and unbalanced in its treatment of homeopathy.

Debate about Homeopathy: Mere Placebo or Great Medicine?

Published on 5 Dec 2012

This question has been harshly argued for more than 200 years. And for more than 200 years, the two positions in this conflict have remained in a complete deadlock. It is astonishing to note that arguments on either side have essentially not changed much over this long period of time. On one side, skeptics are claiming from a purely theoretical point of the view, "homeopathy is implausible. Therefore it can't work," and any evidence in its favor must logically be flawed. On the other hand, we have generations after generations of homeopaths claiming from a purely factual point of view and with loads of evidence, "And yet, it works!"

Dr. André Saine, Dean of the Canadian Academy of Homeopathy, and Dr. Joe Schwarcz, Director of McGill Office for Science and Society, will face each other to debate this important question.

Post-Debate Questions & Answers: After the debate, Drs. André Saine and Joe Schwarcz mutually accepted to answer questions from the public by writing. Dr. Schwarcz also sent 18 questions to Dr. Saine. In return, Dr. Saine sent 27 questions to Dr. Schwarcz. They both agreed to post all four series of Q&A on their respective website. These Q&A can now be accessed here: http://homeopathy.ca/debates_2012-11-... http://homeopathy.ca/debates_2012-11-... http://homeopathy.ca/debates_2012-11-... http://homeopathy.ca/debates_2012-11-...

These Q&A should also be available at: http://blogs.mcgill.ca/oss/2012/12/20...

https://www.youtube.com/watch?v=T2uBBU4XT7Y

Research Randomised placebo-controlled trials of individualised homeopathic treatment: systematic review and meta-analysis Robert T Mathie1*, Suzanne M Lloyd2, Lynn A Legg3, Jürgen Clausen4, Sian Moss5, Jonathan RT Davidson6 and Ian Ford2

Abstract

Background

A rigorous and focused systematic review and meta-analysis of randomised controlled trials (RCTs) of individualised homeopathic treatment has not previously been undertaken. We tested the hypothesis that the outcome of an individualised homeopathic treatment approach using homeopathic medicines is distinguishable from that of placebos.

Methods

The review’s methods, including literature search strategy, data extraction, assessment of risk of bias and statistical analysis, were strictly protocol-based. Judgment in seven assessment domains enabled a trial’s risk of bias to be designated as low, unclear or high. A trial was judged to comprise ‘reliable evidence’ if its risk of bias was low or was unclear in one specified domain. ‘Effect size’ was reported as odds ratio (OR), with arithmetic transformation for continuous data carried out as required; OR > 1 signified an effect favouring homeopathy.

Results

Thirty-two eligible RCTs studied 24 different medical conditions in total. Twelve trials were classed ‘uncertain risk of bias’, three of which displayed relatively minor uncertainty and were designated reliable evidence; 20 trials were classed ‘high risk of bias’. Twenty-two trials had extractable data and were subjected to meta-analysis; OR = 1.53 (95% confidence interval (CI) 1.22 to 1.91). For the three trials with reliable evidence, sensitivity analysis revealed OR = 1.98 (95% CI 1.16 to 3.38).

Conclusions

Medicines prescribed in individualised homeopathy may have small, specific treatment effects. Findings are consistent with sub-group data available in a previous ‘global’ systematic review. The low or unclear overall quality of the evidence prompts caution in interpreting the findings. New high-quality RCT research is necessary to enable more decisive interpretation.

Keywords:

Individualised homeopathy; Meta-analysis; Randomised controlled trials; Systematic review

http://www.systematicreviewsjournal.com/content/3/1/142

 

Dr. Toni Bark, M.D. – Do Not Remove Vaccine Exemptions – Some Children Die from Vaccines - See more at: http://vaccineimpact.com/2015/dr-toni-bark-m-d-do-not-remove-vaccine-exemptions-some-children-die-from-vaccines/#sthash.oGJzwTfZ.dpuf Letter sent to Oregon Senator Ferrioli

Letter sent to Oregon Senator Ferrioli

by Dr. Toni Bark Facebook Page

I trained as a pediatric intern at Bellevue NYU and then in Rehab medicine. I quickly was offered the directorship of the pediatric emergency room at Michael Reese Hospital in Chicago.

While I had initially been furious if parents came in and were not up to date on their children’s vaccines, this attitude changed. And changed drastically.

I began to see patterns. Children who were seen in the vaccine clinic would then come to our ER with seizures, respiratory arrest and asthma attacks. I began to realize, not all children respond well to vaccination and in fact, some die.

It wasn’t until my masters program in disaster management at BU, which I began in 2010 and finished in 2012, did I begin to see the fraudulent nature of how vaccines are being marketed and the corruption in the advisory committees.

I had not even been made aware of the federal vaccine court. I had no idea vaccine recipients who were damaged or killed from vaccines had zero recourse with the manufacturer or physician.

Vaccine manufacturers enjoy full immunity from law suits of any kind, including defective design (as opined by Scalia in Feb 2011) as they are legally listed as “unavoidably unsafe”.

The vaccine court is almost a secret. They have paid out 3 billion dollars since it’s inception in 1986. The vaccine adverse events reporting system is also not well advertised and the government admits it probably only receives 10 percent of the adverse events which occur.

We mandate more vaccines than any other country. We also have the worst infant mortality rate of any first, second, and even some third world countries.

I am 55, so I only received a handful of vaccines. Today, infants receive 14 different vaccines by age of 1 and by age 18, that number is 58 and in some states with flu vaccine mandates, that number is much higher.

A note on the flu vaccine mandates. New Jersey and Connecticut were the first states to mandate flu vaccine for all preschoolers and school age children, annually. This has done nothing to reduce flu cases in their states.In fact, both states are in the highest grouping for flu every year.

While most people do just fine with vaccination, a small percentage do not. And I mean, really do not. Vaccination product inserts describe encephalitis as a possible outcome along with guillan barre paralysis.

Most parents or doctors (for that matter) do not start out “anti-vaccine”, their stance is changed once they have a child who is permanently and profoundly damaged by a vaccine. They then decide no more for that child and no more for their next children.

And they are correct in making that decision.

Genetics, epigenetics and timing can have a great influence on vaccine adverse events. No one drug at one dose is right for everyone and to assume it is, is foolishness.

It is evident from numerous federal cases against many pharmaceutical companies, drug study data is hidden, manipulated and even manufactured. Why is this hard to believe when it comes to vaccine studies?

While I wrote for my masters, I uncovered serious issues with vaccine trials, safety, being one of them. All vaccine safety studies are using false placebos to compare adverse events. The HPV vaccine (which is no longer governmentally recommended in Japan, France and Israel due to serious reactions including deaths) used the new aluminum adjuvant as the placebo. The Prevner safety study, used an experimental meningitis C vaccine.

All the independent Cochrane meta-analysis on vaccine studies end the same way: safety studies are needed in order to assess risk/benefit ratios. There are over 200 new vaccines in the pipeline and as those before them, they will all be approved and recommended which will turn to mandates. When is enough, enough?

After Nazi Germany, the Nuremberg laws were changed to forbid forced medical procedures. The Helsinki accord is very clear; all patients have the right to informed consent prior to medical procedures.

There is no informed consent for vaccination as it is, we really should not be moving backwards.

I am more than willing to send you any studies, to speak to you, or even to fly out and give a presentation.

Watch the Movie Bought for FREE for a limited time.

About Dr. Toni Bark

Dr. Bark received her Bachelor of Science degree in Psychology from The University of Illinois in 1981 and her medical degree from Rush Medical School in 1986.

Dr. Bark completed her Pediatric Residency training at the University of Illinois, Chicago, in 1991, and trained at New York University in Pediatrics from 1986 through 1987 and Rehabilitation Medicine from 1987 through 1988. Immediately post-residency, Dr. Bark worked as attending staff in the Neo-Natal Intensive Care Unit at Michael Reese Hospital. She then took a position as the Director of the Pediatric Emergency Room at Michael Reese Hospital until 1993 when her commitment to natural remedies led her to begin her study of Holistic Medicine.

She has maintained a private practice in Homeopathy for more than fifteen years and was the Medical Director for the integrative Medicine department of Advocate Health Care Systems at Good Shepherd Hospital from June of 2000 until July of 2003.

In 2012 Dr. Bark was bestowed the honor of becoming the 2nd Vice President of the American Institute of Homeopathy (AIH). She also received her Masters in Healthcare Emergency Management (MHEM) from Boston University Medical School that same year.

- See more at: http://vaccineimpact.com/2015/dr-toni-bark-m-d-do-not-remove-vaccine-exemptions-some-children-die-from-vaccines/#sthash.oGJzwTfZ.dpuf

http://vaccineimpact.com/2015/dr-toni-bark-m-d-do-not-remove-vaccine-exemptions-some-children-die-from-vaccines/